The chapter on Walgreens Boots Alliance as a publicly traded entity has officially closed. In August 2025, the company was acquired by private equity firm Sycamore Partners in a deal valued at approximately $10 billion. This transaction precipitated the removal of Walgreens stock from the Nasdaq exchange, and it subsequently exited major indices, including the S&P 500 and the Dow Jones Industrial Average.
Final Financial Report Highlights Deep-Seated Challenges
The imperative for this strategic shift was underscored by the company’s final financial disclosures as a public entity. For the third quarter of 2025, Walgreens reported revenue of $39.0 billion, marking a 7.2 percent increase. However, this top-line growth masked significant underlying issues, as earnings per share plummeted from a profit of $0.40 to a loss of $0.20.
Persistent weaknesses in retail sales and escalating operational expenses proved too substantial to be offset by existing cost-saving initiatives. These figures highlighted the structural difficulties that made the radical corporate overhaul a necessity for the new owners.
Should investors sell immediately? Or is it worth buying Walgreens?
A Strategic Overhaul Under Private Ownership
With the transition to private ownership, Sycamore Partners has initiated a comprehensive restructuring plan designed to restore core profitability. The cornerstone of this strategy involves dismantling the pharmaceutical giant into five distinct, standalone business units.
Concurrently, a rigorous cost-reduction program is underway, targeting the closure of 1,200 store locations over the coming three-year period. The broader restructuring focuses on several key operational improvements:
- Streamlining the remaining retail pharmacy network
- Implementing stringent control over general operating expenditures
- Enhancing cash flow generation capabilities
- Revising executive and employee compensation structures
This aggressive repositioning marks a definitive new beginning for the company, albeit one that public market investors will no longer participate in directly.
Ad
Walgreens Stock: Buy or Sell?! New Walgreens Analysis from January 1 delivers the answer:
The latest Walgreens figures speak for themselves: Urgent action needed for Walgreens investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 1.
Walgreens: Buy or sell? Read more here...
